Mr Harry S. Pangas > Dechert LLP > Washington DC, United States > Lawyer Profile
Dechert LLP Offices
1900 K STREET, NW
WASHINGTON DC 20006
- Go to...
Mr Harry S. Pangas
Corporate & Securities
With more than 20 years of securities regulatory and capital markets experience, Harry S. Pangas has developed a deep and broad practice representing business development companies (BDCs), registered closed-end funds (CEFs), private investment funds, blockchain and cryptocurrency companies, and other financial services firms in connection with a range of securities regulatory and transactional matters.
Having begun his career at the SEC serving in various roles in the Division of Corporation Finance, Mr. Pangas brings a unique insider perspective and knowledge to his work on a daily basis. He regularly counsels BDCs and CEFs on regulatory and compliance matters under the Investment Company Act of 1940 and the Investment Advisers Act of 1940. He advises clients on establishing and operating public and private BDCs and CEFs, and assists alternative investment managers in developing permanent capital structures for their various asset classes. In addition, Mr. Pangas serves as independent counsel to the independent directors of the nation’s largest BDC and has been involved in a large number of strategic transactions and proxy contests in the closed-end fund space.
Mr. Pangas regularly advises public companies on compliance with ongoing SEC reporting obligations and other securities laws, including Section 16 compliance, Rule 10b5-1 plans, the Sarbanes-Oxley Act, Form S-8, Rule 144 and proxy statement and executive compensation disclosure, as well as the corporate governance listing requirements of the NYSE and Nasdaq.
In addition, Mr. Pangas represents issuers and investment banking firms in connection with public and private offerings of equity and debt securities, including initial public offerings (IPOs), Rule 144A offerings, shelf offerings, at-the-market offerings (ATMs), registered direct offerings, high-yield bond offerings, convertible debt offerings and rights offerings. To date, Harry has been involved in more than 100 debt and equity offerings, including 15 initial public offerings, raising in excess of US$15 billion in gross proceeds.
American Bar Association; District of Columbia Bar – Tax Section
Syracuse University, B.A., cum laude; Tulane University Law School, J.D., cum laude
‘Collaborative, involved, professional and prompt’, Dechert LLP attracts praise for ‘seeking to understand the client’s business to provide a value-add service’. The group, which acts for corporate issuers and investment banks, is particularly prominent in advising business development companies and life sciences clients on equity deals. Among its recent highlights, Philadelphia-based private equity specialist Kenneth Young advised Corporate Capital Trust, a business development company, on its NYSE listing. New York-based group co-chair David Rosenthal (‘a trusted and valued advisor’) acted alongside Philadelphia’s Gregory Schernecke to advise Aquestive Therapeutics on its $67.5m IPO. Other key contacts include Boston-based department co-chair Thomas Friedmann, Philadelphia-based James Lebovitz and business development company specialist Harry Pangas, who recently joined in Washington DC from Eversheds Sutherland.
Top Tier Firm Rankings
- Dispute resolution > International litigation
- Antitrust > Merger control
- Investment fund formation and management > Mutual/registered/ exchange-traded funds
- Finance > Structured finance: securitization
- Antitrust > Civil litigation/class actions: defense
- Dispute resolution > Corporate investigations and white-collar criminal defense
- Dispute resolution > E-discovery
- Dispute resolution > General commercial disputes
- Tax > International tax
- Dispute resolution > Product liability, mass tort and class actions: pharmaceuticals and medical devices - defense
- Real estate > Real estate
- Real estate > Real estate
- Dispute resolution > Securities litigation - defense
- Intellectual property > Trademarks: non-contentious (including prosecution, portfolio management and licensing)
- Finance > Capital markets: equity offerings
- Labor and employment > Employee benefits, executive compensation and retirement plans: transactional
- Industry focus > Healthcare: life sciences
- Dispute resolution > M&A litigation: defense
- M&A/corporate and commercial > Private equity buyouts
- Dispute resolution > Product liability, mass tort and class actions: toxic tort - defense
- Investment fund formation and management > Alternative/hedge funds
- Finance > Capital markets: debt
- Finance > Capital markets: global offerings
- Finance > Capital markets: high-yield debt offerings
- Finance > Commercial lending
- Labor and employment > Employee benefits, executive compensation and retirement plans: design
- Dispute resolution > International arbitration
- Dispute resolution > International trade
- Finance > Restructuring (including bankruptcy): corporate
- Tax > US taxes: non-contentious
- M&A/corporate and commercial > M&A: large deals ($1bn+)
- Investment fund formation and management > Private equity funds (including venture capital)
- Finance > Financial services regulation